1.Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT: Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011, 1:a006189.
2.Klein WL, Stine WB, Jr., Teplow DB: Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol Aging 2004, 25:569–580.
3.Park SK, Ha JS, Kim JM, Kang JY, Lee du S, Guo TJ, Lee U, Kim DO, Heo HJ: Antiamnesic Effect of Broccoli (Brassica oleracea var. italica) Leaves on Amyloid Beta (Abeta)1–42-Induced Learning and Memory Impairment. J Agric Food Chem 2016, 64:3353–3361.
4.Herrmann N, Chau SA, Kircanski I, Lanctot KL: Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs 2011, 71:2031–2065.
5.Hensley K: Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 2010, 21:1–14.
6.Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al: Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015, 14:388–405.
7.Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010, 330:1774.
8.Minter MR, Taylor JM, Crack PJ: The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J Neurochem 2016, 136:457–474.
9.Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML: Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012, 9:8.
10.Pan RY, Ma J, Kong XX, Wang XF, Li SS, Qi XL, Yan YH, Cheng J, Liu Q, Jin W, et al: Sodium rutin ameliorates Alzheimer’s disease-like pathology by enhancing microglial amyloid-beta clearance. Sci Adv 2019, 5:eaau6328.
11.Hjorth E, Frenkel D, Weiner H, Schultzberg M: Effects of immunomodulatory substances on phagocytosis of abeta(1–42) by human microglia. Int J Alzheimers Dis 2010, 2010.
12.Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, et al: An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 2012, 32:9677–9689.
13.Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, Green KN: Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 2014, 82:380–397.
14.Wes PD, Sayed FA, Bard F, Gan L: Targeting microglia for the treatment of Alzheimer’s Disease. Glia 2016, 64:1710–1732.
15.Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al: Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 2016, 540:230–235.
16.Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, Chen J: Microglial and macrophage polarization-new prospects for brain repair. Nat Rev Neurol 2015, 11:56–64.
17.Cherry JD, Olschowka JA, O’Banion MK: Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014, 11:98.
18.David S, Kroner A: Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 2011, 12:388–399.
19.Bok E, Chung YC, Kim KS, Baik HH, Shin WH, Jin BK: Modulation of M1/M2 polarization by capsaicin contributes to the survival of dopaminergic neurons in the lipopolysaccharide-lesioned substantia nigra in vivo. Exp Mol Med 2018, 50:76.
20.Saijo K, Glass CK: Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011, 11:775–787.
21.Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M: Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013, 229:176–185.
22.Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153–183.
23.Dimri M, Humphries A, Laknaur A, Elattar S, Lee TJ, Sharma A, Kolhe R, Ande S: Nqo1 ablation inhibits activation of the PI3K/Akt and MAPK/ERK pathways and blocks metabolic adaptation in hepatocellular carcinoma. Hepatology 2019.
24.Koistinaho M, Koistinaho J: Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 2002, 40:175–183.
25.Sun A, Liu M, Nguyen XV, Bing G: P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp Neurol 2003, 183:394–405.
26.Schnoder L, Hao W, Qin Y, Liu S, Tomic I, Liu X, Fassbender K, Liu Y: Deficiency of Neuronal p38alpha MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. J Biol Chem 2016, 291:2067–2079.
27.Feld M, Krawczyk MC, Sol Fustinana M, Blake MG, Baratti CM, Romano A, Boccia MM: Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer’s disease. J Alzheimers Dis 2014, 40:69–82.
28.Munoz L, Ammit AJ: Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology 2010, 58:561–568.
29.Bachstetter AD, Rowe RK, Kaneko M, Goulding D, Lifshitz J, Van Eldik LJ: The p38alpha MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci 2013, 33:6143–6153.
30.Zhang B, Wei YZ, Wang GQ, Li DD, Shi JS, Zhang F: Targeting MAPK Pathways by Naringenin Modulates Microglia M1/M2 Polarization in Lipopolysaccharide-Stimulated Cultures. Front Cell Neurosci 2018, 12:531.
31.Kitayama T, Okamoto T, Hill RK, Kawai Y, Takahashi S, Yonemori S, Yamamoto Y, Ohe K, Uemura S, Sawada S: Chemistry of Zerumbone. 1. Simplified Isolation, Conjugate Addition Reactions, and a Unique Ring Contracting Transannular Reaction of Its Dibromide. J Org Chem 1999, 64:2667–2672.
32.Haque MA, Jantan I, Arshad L, Bukhari SNA: Exploring the immunomodulatory and anticancer properties of zerumbone. Food Funct 2017, 8:3410–3431.
33.Ashraf SM, Sebastian J, Rathinasamy K: Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel. Cell Prolif 2019, 52:e12558.
34.Yob NJ, Jofrry SM, Affandi MM, Teh LK, Salleh MZ, Zakaria ZA: Zingiber zerumbet (L.) Smith: A Review of Its Ethnomedicinal, Chemical, and Pharmacological Uses. Evid Based Complement Alternat Med 2011, 2011:543216.
35.Haque MA, Jantan I, Harikrishnan H: Zerumbone suppresses the activation of inflammatory mediators in LPS-stimulated U937 macrophages through MyD88-dependent NF-kappaB/MAPK/PI3K-Akt signaling pathways. Int Immunopharmacol 2018, 55:312–322.
36.Kim MJ, Yun JM: Molecular Mechanism of the Protective Effect of Zerumbone on Lipopolysaccharide-Induced Inflammation of THP–1 Cell-Derived Macrophages. J Med Food 2019, 22:62–73.
37.Chen BY, Lin DP, Wu CY, Teng MC, Sun CY, Tsai YT, Su KC, Wang SR, Chang HH: Dietary zerumbone prevents mouse cornea from UVB-induced photokeratitis through inhibition of NF-kappaB, iNOS, and TNF-alpha expression and reduction of MDA accumulation. Mol Vis 2011, 17:854–863.
38.Gopalsamy B, Farouk AAO, Tengku Mohamad TAS, Sulaiman MR, Perimal EK: Antiallodynic and antihyperalgesic activities of zerumbone via the suppression of IL–1beta, IL–6, and TNF-alpha in a mouse model of neuropathic pain. J Pain Res 2017, 10:2605–2619.
39.Lim CS, Jin DQ, Mok H, Oh SJ, Lee JU, Hwang JK, Ha I, Han JS: Antioxidant and antiinflammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia. J Neurosci Res 2005, 82:831–838.
40.Shi C, Zheng DD, Wu FM, Liu J, Xu J: The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3beta pathway mediates bilobalide-induced reduction in amyloid beta-peptide. Neurochem Res 2012, 37:298–306.
41.Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, et al: Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940–946.
42.Gengler S, Hamilton A, Holscher C: Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer’s disease is impaired in old but not young mice. PLoS One 2010, 5:e9764.
43.Lepore F, D’Alessandro G, Antonangeli F, Santoro A, Esposito V, Limatola C, Trettel F: CXCL16/CXCR6 Axis Drives Microglia/Macrophages Phenotype in Physiological Conditions and Plays a Crucial Role in Glioma. Front Immunol 2018, 9:2750.
44.Lee JK, Tansey MG: Microglia isolation from adult mouse brain. Methods Mol Biol 2013, 1041:17–23.
45.Pan B, Yang L, Wang J, Wang Y, Wang J, Zhou X, Yin X, Zhang Z, Zhao D: C-Abl tyrosine kinase mediates neurotoxic prion peptide-induced neuronal apoptosis via regulating mitochondrial homeostasis. Mol Neurobiol 2014, 49:1102–1116.
46.Pan Y, Sun L, Wang J, Fu W, Fu Y, Wang J, Tong Y, Pan B: STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis. Neuropharmacology 2015, 93:191–198.
47.Pan B, Zhang H, Cui T, Wang X: TFEB activation protects against cardiac proteotoxicity via increasing autophagic flux. J Mol Cell Cardiol 2017, 113:51–62.
48.Zhang H, Pan B, Wu P, Parajuli N, Rekhter MD, Goldberg AL, Wang X: PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy. Sci Adv 2019, 5:eaaw5870.
49.Wesson DW, Wilson DA: Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res 2011, 216:408–413.
50.Bolivar VJ, Walters SR, Phoenix JL: Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res 2007, 176:21–26.
51.Hibbits N, Pannu R, Wu TJ, Armstrong RC: Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro 2009, 1.
52.de Chaumont F, Dallongeville S, Chenouard N, Herve N, Pop S, Provoost T, Meas-Yedid V, Pankajakshan P, Lecomte T, Le Montagner Y, et al: Icy: an open bioimage informatics platform for extended reproducible research. Nat Methods 2012, 9:690–696.
53.Zhang Z, Zhang ZY, Fauser U, Schluesener HJ: FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 2008, 210:681–690.
54.Rae F, Woods K, Sasmono T, Campanale N, Taylor D, Ovchinnikov DA, Grimmond SM, Hume DA, Ricardo SD, Little MH: Characterisation and trophic functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP transgene reporter. Dev Biol 2007, 308:232–246.
55.Li D, Lang W, Zhou C, Wu C, Zhang F, Liu Q, Yang S, Hao J: Upregulation of Microglial ZEB1 Ameliorates Brain Damage after Acute Ischemic Stroke. Cell Rep 2018, 22:3574–3586.
56.Bolouri H, Savman K, Wang W, Thomas A, Maurer N, Dullaghan E, Fjell CD, Ek CJ, Hagberg H, Hancock RE, et al: Innate defense regulator peptide 1018 protects against perinatal brain injury. Ann Neurol 2014, 75:395–410.
57.Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O: Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 2003, 100:13632–13637.
58.Lee CY, Chen SP, Su CH, Ho YC, Yang ML, Lee SS, Huang-Liu R, Yang CP, Chen CJ, Kuan YH: Zerumbone from Zingiber zerumbet Ameliorates Lipopolysaccharide-Induced ICAM–1 and Cytokines Expression via p38 MAPK/JNK-IkappaB/NF-kappaB Pathway in Mouse Model of Acute Lung Injury. Chin J Physiol 2018, 61:171–180.
59.Zhang ZY, Schluesener HJ: Oral administration of histone deacetylase inhibitor MS–275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J Neuropathol Exp Neurol 2013, 72:178–185.
60.Yao XQ, Jiao SS, Saadipour K, Zeng F, Wang QH, Zhu C, Shen LL, Zeng GH, Liang CR, Wang J, et al: p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer’s disease. Mol Psychiatry 2015, 20:1301–1310.
61.Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ, Liu J, Zhu C, Shen LL, Liu CH, et al: Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A 2015, 112:5225–5230.
62.Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, et al: p38 kinase is activated in the Alzheimer’s disease brain. J Neurochem 1999, 72:2053–2058.
63.Sun J, Nan G: The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review). Int J Mol Med 2017, 39:1338–1346.
64.Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I: Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer’s disease. Brain Res Mol Brain Res 2002, 109:45–55.
65.Yokota T, Wang Y: p38 MAP kinases in the heart. Gene 2016, 575:369–376.
66.Yasuda S, Sugiura H, Tanaka H, Takigami S, Yamagata K: p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 2011, 11:45–59.
67.Song XY, Hu JF, Sun MN, Li ZP, Zhu ZX, Song LK, Yuan YH, Liu G, Chen NH: IMM-H004, a novel coumarin derivative compound, attenuates the production of inflammatory mediatory mediators in lipopolysaccharide-activated BV2 microglia. Brain Res Bull 2014, 106:30–38.
68.Shi ZM, Han YW, Han XH, Zhang K, Chang YN, Hu ZM, Qi HX, Ting C, Zhen Z, Hong W: Upstream regulators and downstream effectors of NF-kappaB in Alzheimer’s disease. J Neurol Sci 2016, 366:127–134.
69.Ju Hwang C, Choi DY, Park MH, Hong JT: NF-kappaB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease. CNS Neurol Disord Drug Targets 2019, 18:3–10.
70.Jones SV, Kounatidis I: Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans. Front Immunol 2017, 8:1805.
71.Jang JH, Surh YJ: Beta-amyloid-induced apoptosis is associated with cyclooxygenase–2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic Biol Med 2005, 38:1604–1613.
72.Chami L, Buggia-Prevot V, Duplan E, Del Prete D, Chami M, Peyron JF, Checler F: Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 2012, 287:24573–24584.
73.Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ, Watterson DM: A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer’s disease mouse model. J Neuroinflammation 2007, 4:21.
74.Roy SM, Grum-Tokars VL, Schavocky JP, Saeed F, Staniszewski A, Teich AF, Arancio O, Bachstetter AD, Webster SJ, Van Eldik LJ, et al: Targeting human central nervous system protein kinases: An isoform selective p38alphaMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models. ACS Chem Neurosci 2015, 6:666–680.
75.Lee JK, Kim NJ: Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease. Molecules 2017, 22.
76.de las Heras B, Hortelano S: Molecular basis of the anti-inflammatory effects of terpenoids. Inflamm Allergy Drug Targets 2009, 8:28–39.
77.Murakami A, Takahashi D, Kinoshita T, Koshimizu K, Kim HW, Yoshihiro A, Nakamura Y, Jiwajinda S, Terao J, Ohigashi H: Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis 2002, 23:795–802.
78.Takada Y, Murakami A, Aggarwal BB: Zerumbone abolishes NF-kappaB and IkappaBalpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 2005, 24:6957–6969.
79.Ownby RL: Neuroinflammation and cognitive aging. Curr Psychiatry Rep 2010, 12:39–45.
80.Rodriguiz RM, Wetsel WC: Assessments of Cognitive Deficits in Mutant Mice. In Animal Models of Cognitive Impairment. Edited by Levin ED, Buccafusco JJ. Boca Raton (FL); 2006: Frontiers in Neuroscience]..
81.Alexander G, Hanna A, Serna V, Younkin L, Younkin S, Janus C: Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer’s disease. Behav Brain Res 2011, 216:77–83.
82.Deacon RM: Assessing nest building in mice. Nat Protoc 2006, 1:1117–1119.
83.Bechara A: The neurology of social cognition. Brain 2002, 125:1673–1675.
84.Hari R, Kujala MV: Brain basis of human social interaction: from concepts to brain imaging. Physiol Rev 2009, 89:453–479.
85.Hemonnot AL, Hua J, Ulmann L, Hirbec H: Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Front Aging Neurosci 2019, 11:233.
86.Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ: Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer’s disease. J Neuroinflammation 2005, 2:9.
87.Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, Luo W, Li Y, Caracciolo L, Russo I, et al: Tumor necrosis factor-alpha synthesis inhibitor 3,6’-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation 2012, 9:106.
88.Mandrekar-Colucci S, Karlo JC, Landreth GE: Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci 2012, 32:10117–10128.
89.Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al: NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674–678.
90.Bhat NR, Feinstein DL, Shen Q, Bhat AN: p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells. Roles of nuclear factors, nuclear factor kappa B, cAMP response element-binding protein, CCAAT/enhancer-binding protein-beta, and activating transcription factor–2. J Biol Chem 2002, 277:29584–29592.
91.Guo L, Du H, Yan S, Wu X, McKhann GM, Chen JX, Yan SS: Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer’s neurons. PLoS One 2013, 8:e54914.
92.Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, Ferrario M, Borsani G, Spano P, Pizzi M: NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 2006, 23:1711–1720.